Agilent Technologies Q4 revenue $1.04 billion, down 1%
Fourth-quarter GAAP income from continuing operations was $140 million, or $0.42 per share. Last year's fourth-quarter GAAP loss from continuing operations was $26 million, or a loss of $0.08 per share.
During the fourth quarter, Agilent had intangible amortization of $37 million, transformation costs of $15 million, acquisition and integration costs of $7 million, asset impairments of $3 million, and a tax benefit of $39 million.
Excluding these items, and $5 million of other costs, Agilent reported fourth-quarter adjusted income from continuing operations of $168 million, $0.50 per share.
Fourth-quarter revenue of $515 million from Agilent's Life Sciences and Applied Markets Group (LSAG) declined 4 percent year over year (up 2 percent on a core basis). Strong performance in pharma was offset by softness in the industrial market and in the academia and government market. LSAG's Q4 operating margin was 20 percent.
Fourth-quarter revenue of $342 million from the Agilent CrossLab Group (ACG) grew 3 percent year over year, up 11 percent on a core basis. Both services and consumables experienced strong growth across all geographies. ACG's operating margin was 25.1 percent in the quarter.
Fourth-quarter revenue of $178 million from Agilent's Diagnostics and Genomics Group (DGG) increased 4 percent year over year, up 10 percent on a core basis, reflecting continued strength across all of its businesses. DGG's operating margin for the quarter was 19.2 percent.
Agilent expects first-quarter 2016 revenue in the range of $1 billion to $1.02 billion. First-quarter non-GAAP earnings are expected to be in the range of $0.42 to $0.44 per share.
For fiscal year 2016, Agilent expects revenue of $4.15 billion to $4.17 billion and non-GAAP earnings of $1.85 to $1.91 per share. The guidance is based on Oct. 30, 2015, exchange rates. ■